positive margins ; p < 0.0001], ECE ; p < 0.0001], SVI ; p < 0.0001], and Gleason score [8] [9] [10] ; p < 0.0001]. Cancer centre was also predictive of referral rates (range 5.68% to 65.63% p < 0.0001). Patients seen by RO post-RP were almost twice as likely to have seen RO prior to RP ; p < 0.0001]. Patient age, distance from an RT facility, neighbourhood income quintile, RP centre surgical volume, and affiliation of RP hospital with a cancer centre were not associated with the likelihood of RO consultation. On multivariate analysis of determinants of receiving ART, younger age [OR 1.029(1.004-1.054); p = 0.024] and adverse pathologic features, including positive margins ; p < 0.0001], ECE ; p < 0.0001], SVI ; p < 0.0001], and Gleason score 8-10 [OR 2.53(1.68-3.82); p < 0.0001] remained strongly associated with the use of ART. The use of ART varied significantly across cancer centre regions (range 1.14% to 19.37% of all RP patients, p = 0.0002). Conclusions: Over 40% of patients have high-risk features following RP and may benefit from ART, but many do not receive early RO referral. Cancer Centre is strongly predictive of both referral and ART use. An effort should be made to understand and reduce large inter-centre variations in access to RT post-RP for patients with high-risk prostate cancer. Ezra Hahn, Juan P. Velazquez-Martin, Sohel Somani, David Payne, John Waldron, Hatem Krema, Rand Simpson, Normand Laperriere, Caroline Chung University of Toronto, Toronto, ON Purpose: Choroidal metastases are an ominous sign of advanced systemic disease and a substantial source of morbidity causing visual impairment in many. External beam radiotherapy (RT) is an effective palliative treatment for choroidal metastases aimed at preserving vision and obtaining local tumour control. This study reports the outcomes of delivery of 20 Gy in 5 fractions in this palliative setting. Methods and Materials: This retrospective chart review included patients treated in the Ocular Oncology clinic at a large tertiary cancer centre who received RT (20 Gy in 5 fractions) for choroidal metastases between January 1999 and November 2012. Primary outcome measures were change in visual acuity and tumour response. Secondary outcomes included toxicities of RT (CTCAE version 4.0), tumour control, and overall survival (OS) from the date of choroidal metastases diagnosis. The following variables were evaluated using univariate and multivariable cox regression models for their association with OS: tumour histology, presence of symptoms, number of choroidal metastases, unilateral versus bilateral choroidal involvement, and interval between primary cancer diagnoses and choroidal metastases. Results: Fifty-five patients with 71 involved eyes were evaluated. Median follow up was 12 months (range 1-49). Decreased vision was the presenting symptom in 43 eyes (61%). Visual acuity improved from a median of 20/70 at baseline to 20/40 at last follow up, and remained stable or improved in 56 eyes (80%). Tumour shrinkage was observed in 64 eyes (91%) with complete response in 47 eyes (67%). Metastases progressed in four eyes (6%). Of the 39 patients presenting with unilateral choroidal disease (all were treated with a single lateral field, which resulted in 50-80% of the prescription dose to the contralateral choroid), only one developed contralateral choroidal metastases at 11 months after RT. Median survival after diagnosis of choroidal metastases was 13 months (95% CI: 9-19) with Kaplan-Meier estimates of 50% (36-62), 23% (12-35), and 8% (3-18) at one, two, and three years, respectively. Acute toxicities were not experienced in 49 (89%) patients while five patients had transitory eye dryness (Grade 1) and one patient had episcleritis (Grade 1). Late toxicities included seven (10%) with optic neuropathy, four (6%) with cataracts, one (1%) with retinopathy, five (7%) with pigmentary maculopathy, and one (1%) with neovascular glaucoma. No variables were statistically significantly associated with OS. Conclusions: A short fractionation schedule of 20 Gy in 5 fractions is a well-tolerated treatment that effectively preserves vision and gains local tumour control for many patients with choroidal metastases. This approach minimizes time spend in hospital for this palliative patient population and compares favourably to previously reported series for both outcomes and toxicities. Purpose: The Spinal Instability Neoplastic Score (SINS) was developed to identify patients requiring assessment by a spine surgeon. Patients are stratified into three groups: score 0-6 (stable spine, no referral), 7-12 (potentially unstable, consider referral), and 13-18 (unstable, referral required). Purposes of study: (1) characterize the scores seen in a consecutive cohort of patients treated with spinal radiotherapy (RT) (2) assess referral patterns to spinal surgery (3) identify whether high SINS was prognostic of worse outcome following palliative RT.
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Methods and Materials:
We retrospectively reviewed consecutive patients receiving palliative spine RT between 2012 and 2013. The SINS was calculated based on CT simulation scan and clinical assessment. Charts were reviewed. Data analyzed using Kaplan-Meier and Cox models. A threshold of seven stratified patients into low-versus high-SINS groups. Results: One hundred and ninety-six patients were included. Patient demographics (median(range)): Age 66 (34-95), ECOG 2 (0-4), Charlson Comorbidity Score 0 (0-4). Follow up was 6.1 (0.1-42.3) months in all patients and 28.5 (0.2-42.3) months in living patients. By time of analysis, 83.7% had died. Median (range) SINS was 7 (1-18). SINS was 0-6, 7-12, and 13-18 in 34%, 59% and 7% of patients. SINS indicated potentially or unstable spine in 84%, 63%, 53%, and 62% of breast, lung, prostate, and other cancer patients. Nineteen patients were referred to spine surgery (13 before and six after RT), with a surgery performed in zero of two patients with SINS 0-6, three of 14 with SINS 7-12, and one of three with SINS 13-18. Stable spine on assessment, intact neurological status, and poor life expectancy were the most common reasons not to pursue surgery amongst surgically referred patients. SINS > 7, age, ECOG > 2, cancer type, solitary vertebral metastasis, control of primary, systemic therapy, and estimated prognosis were not predictive of surgery referral on univariate analysis. Outcomes (median(95%CI)) did not differ between low-versus high-SINS groups. Overall survival was 7.1 months (4.4-9.8, low) versus 6.4 months (2.1-10.5, high), p = 0.262. Time to ECOG ≥ 3 was 17.1 months (5.2-28.9, low) versus 22.0 months (20.8-23.1, high), p = 0.167. Freedom from subsequent intervention (RT or surgery) to the same vertebrae at one year was 81.7 +/-5.5% (low) versus 79.0% +/-5.4% (high), p = 0.211. Ambulation at one year was 84.2 +/-4.7% (low) versus 90.2 +/-4.0% (high), p = 0.085. Conclusions: Most patients with unstable or potentially unstable spines according to SINS were not referred to a spine surgeon. Higher SINS did not predict for worse survival, functional outcomes, or increased need for subsequent intervention. It is uncertain whether SINS would be predictive of outcomes in a cohort with better performance status. At the time of this study, many physicians were not using SINS to guide referral decisions. Whether and how SINS should be used to select patients for surgery requires further study.
